북미 림프부종 치료 시장, 치료 유형(압박 요법, 수술, 약물 요법, 레이저 요법 및 기타), 유형(1차 림프부종 및 2차 림프부종), 영향을 받는 부위(생식기, 하지, 상지), 연령대(성인, 소아 및 노인), 투여 경로(경구, 주사 및 국소), 최종 사용자(병원, 외래 수술 센터, 전문 클리닉 및 기타), 유통 채널(직접 입찰, 약국 매장 및 기타) 2029년까지의 산업 동향 및 예측
북미 림프부종 치료 시장 분석 및 통찰력
림프부종은 일반적으로 팔이나 다리 중 하나에 영향을 미칩니다. 어떤 경우에는 팔과 다리가 모두 영향을 받을 수 있습니다. 어떤 환자는 머리, 생식기 또는 가슴이 부어오르는 것을 경험할 수 있습니다.
림프부종은 치료할 수 없지만, 적절한 치료를 통해 조절이 가능하며, 적절한 치료는 붓기와 통증을 줄이는 데 도움이 될 수 있습니다.
복합적 충혈 완화 요법(CDT): 이는 집중적 치료 단계로 시작하며, 이 기간 동안 환자는 매일 치료와 훈련을 받습니다. 그 다음에는 환자가 배운 기술을 사용하여 치료를 맡도록 격려하는 유지 단계가 이어집니다.
돌연변이는 림프계 발달에 관여하는 일부 유전자에서 원발성 림프부종을 일으킬 수 있습니다. 이러한 결함 있는 유전자는 림프계의 발달을 방해하여 체액을 적절히 배출하는 능력을 약화시킵니다.
2차 림프부종에는 암 수술, 방사선 치료, 감염, 염증 상태, 심혈관 질환, 부상 및 외상을 포함한 여러 가지 원인이 있을 수 있습니다.
암 유병률 증가와 의료비 증가로 인해 의료 시설에서 림프부종을 치료해야 할 필요성이 가속화되었습니다. 혁신과 기술의 급증도 시장 성장을 촉진하고 있습니다.
북미 림프부종 치료 시장은 시장의 떠오르는 플레이어와 고급 영상 제품의 가용성으로 인해 예측 연도에 성장하고 있습니다. 이와 함께 제조업체는 시장에 새로운 제품을 출시하기 위한 R&D 활동에 참여하고 있습니다.
전 세계적으로 암 관련 림프부종 환자의 증가와 R&D 활동의 증가는 예측 기간 동안 북미 림프부종 치료 시장에 대한 수요를 촉진하고 있습니다. 그러나 치료법이 없고 치료 비용이 높기 때문에 예측 기간 동안 북미 림프부종 치료 시장 성장이 방해받을 수 있습니다.
Data Bridge Market Research에 따르면 북미 림프부종 치료 시장은 2022년부터 2029년까지의 예측 기간 동안 연평균 성장률 9.7%로 성장할 것으로 예상됩니다.
보고서 메트릭 |
세부 |
예측 기간 |
2022년부터 2029년까지 |
기준 연도 |
2021 |
역사적 연도 |
2020 (2019-2014까지 사용자 정의 가능) |
양적 단위 |
매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시됨 |
다루는 세그먼트 |
By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Type (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genitalia, Lower Extremity, Upper Extremity), Age Group (Adult, Pediatric, and Geriatric), Route of Administration (Oral, Injectable, and Topical), End User (Hospital, Ambulatory Surgical Centres, Speciality Clinics, and Others), Distribution Channel (Direct Tender, Pharmacy Stores, and Others) |
Countries Covered |
U.S., Canada, and Mexico |
Market Players Covered |
Tactile Medical, BIOCOMPRESSION SYSTEMS, Lohmann & Rauscher GmbH & Co. KG, ThermoTek, Essity (BSN medical GmbH), Cardinal Health, Smith+Nephew, Avet Pharmaceuticals Inc., KOYA MEDICAL, SIGVARIS GROUP, AIROS Medical, Inc., Tactile Medical, medi GmbH & Co. KG, PAUL HARTMANN AG, Convatec Inc., 3M, JUZO, Mego Afek ltd, Huntleigh Healthcare Limited, HERANTIS PHARMA Plc, among others |
Market Definition
Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid usually drained through the body's lymphatic system. It most commonly affects the arms or legs but can also occur in the chest wall, abdomen, neck, and genitals.
Lymph nodes are an important part of your lymphatic system. Lymphedema can be caused by cancer treatments that remove or damage your lymph nodes. Any problem that blocks the drainage of lymph fluid can cause lymphedema.
Treatment may include compression bandages, massage, compression stockings, sequential pneumatic pumping, careful skincare, and surgery to remove swollen tissue or create new drainage routes.
The high prevalence of cancers, increasing innovations and technologies and rising number of players in the market, and novel product launches also propel the market's growth.
North America Lymphedema Treatment Market Dynamics
Drivers
- Rise in the number of Lymphedema Cases
The collection of lymph fluid in fatty tissues close beneath the skin is called lymphedema. The ailment is caused by a person's poor lymphatic system flow, and it manifests itself in the legs, arms, or both. Primary lymphedema affects one to two million persons in the United States, while secondary lymphedema affects two to three million.
- Increase in the Prevalence of Cancers
According to the National Cancer Institute, 1,806,590 new cancer cases will be identified in the United States in 2020, with 606,520 people dying from the disease.
According to the American Cancer Society, Inc, cancer is the main cause of death in Canada and the second-highest cause in the United States, behind heart disease. In 2018, it was anticipated that 1.9 million new cancer cases and 693,000 cancer deaths would occur in North America.
Furthermore, an increasing number of healthcare facilities and multiple therapies are the factors that will expand the lymphedema treatment market. Additionally, the healthcare system requires highly advanced treatment products. Therefore, major players are highly focused on new and innovative product launches and approvals to drive the North America lymphedema treatment market.
Opportunities
- Drug Approvals
The market has witnessed numerous drug approvals in past years, driven by the increasing fatality rate of disease. Increasing drug approvals will ramp up the demand for the lymphedema treatment market.
In July 2015, Siltuximab was the first drug to be approved to treat multicentric castleman's disease under the FDA priority review program in the US. The multicentric castleman's disease enlarges the lymph nodes with characteristic findings in multiple lymph node regions.
Moreover, partnerships and agreements by major players in North America will boost new opportunities for the market's growth rate.
Restraints/Challenges
However, the high cost of treatment and lack of awareness about lymphedema restrains the market. Furthermore, no permanent cure for lymphedema and difficult reimbursement act as the challenge for the North America lymphedema treatment market
North America lymphedema treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.
COVID-19 Impact on North America Lymphedema Treatment Market
COVID-19 has positively affected the market. On March 11, 2020, COVID-19 was formally declared a pandemic. The COVID-19 pandemic has resulted in an unprecedented demand for healthcare resources since then.
The treatment of both primary and secondary lymphedema patients has been interrupted or delayed during COVID 19. There was a huge decrease in the number of patients visiting hospitals, which impacted the overall growth of the North America lymphedema treatment market. The COVID-19 impact has negatively affected the price of lymphedema treatment products because of the increased cost of drugs and medication prescribed for lymphedema and fewer doctor visits during the lockdown period.
According to United Nations Office on Drugs and Crime (UNODC), mobility restrictions, closed borders, and a decline in overall world trade during COVID-19 disrupted the supply chains of drug markets.
Moreover, many drugs are being produced at different locations, and due to the restrictions on movement, there has been a shortage in the drug supply. Therefore, COVID-19 has a negative impact on the supply chain of the North America lymphedema treatment market.
Recent Developments
- In February 2020, Avet Pharmaceuticals Inc. announced that they acquired a portfolio of 23 abbreviated new drug applications (ANDAs), covering 17 product families, all previously approved by the U.S. Food and Drug Administration (FDA). This broadened the product portfolio of the company
- In September 2021, Tactile Medical announced the enrollment of the first patient in a randomized, controlled clinical trial evaluating the effectiveness of Flexitouch plus for the treatment of head and neck lymphedema. This will increase the credibility of the company in the market
North America Lymphedema Treatment Market Scope
North America lymphedema treatment market is segmented based on treatment type, type, affected area, age group, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Compression Therapy
- Surgery
- Drug Therapy
- Laser Therapy
- Others
On the basis of treatment type, the North America lymphedema treatment market is segmented into compression therapy, surgery, drug therapy, laser therapy, and others.
Type
- Secondary Lymphedema
- Primary Lymphedema
On the basis of type, the North America lymphedema treatment market is segmented into secondary lymphedema and primary lymphedema.
Affected Area
- Lower Extremity
- Upper Extremity
- Genitalia
On the basis of affected area, the North America lymphedema treatment market is segmented into lower extremity, upper extremity, and genitalia
Age Group
- Adult
- Geriatric
- Pediatric
On the basis of age group, the North America lymphedema treatment market is segmented into adult, geriatric, and pediatric.
Route of Administration
- Oral
- Injectable
- Topical
On the basis of route of administration, the North America lymphedema treatment market is segmented into oral, injectable, and topical.
End User
- Hospital
- Speciality Clinics
- Ambulatory Surgical Centers
- Others
Based on end user, the North America lymphedema treatment market is segmented into hospital, speciality clinics, ambulatory surgical centers, and others.
Distribution Channel
- Pharmacy Stores
- Direct Tender
- Others
Based on distribution channel, the North America lymphedema treatment market is segmented into pharmacy stores, direct tender, and others.
North America Lymphedema Treatment Market Regional Analysis/Insights
North America lymphedema treatment market is analyzed, and market size insights and trends are provided by country, treatment type, type, affected area, age group, route of administration, end user, and distribution channel as referenced above.
The countries covered in the North America lymphedema treatment market report are the U.S., Canada, and Mexico.
U.S. is expected to dominate the North America lymphedema treatment market due to the strong presence of market players and the rising prevalence of lymphedema diseases.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels is considered while providing forecast analysis of the country data.
Competitive Landscape and North America Lymphedema Treatment Market Share Analysis
North America lymphedema treatment market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North American presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points are only related to the companies' focus on the North America lymphedema treatment market.
Some of the major players operating in the North America lymphedema treatment market are Tactile Medical, BIOCOMPRESSION SYSTEMS, Lohmann & Rauscher GmbH & Co. KG, ThermoTek, Essity (BSN medical GmbH), Cardinal Health, Smith+Nephew, Avet Pharmaceuticals Inc., KOYA MEDICAL, SIGVARIS GROUP, AIROS Medical, Inc., Tactile Medical, medi GmbH & Co. KG, PAUL HARTMANN AG, Convatec Inc., 3M, JUZO, Mego Afek ltd, Huntleigh Healthcare Limited, HERANTIS PHARMA Plc, among others.
Research Methodology
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용을 알아보려면 분석가 전화를 요청하거나 문의 사항을 드롭 다운하세요. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 아프리카 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의 사항을 드롭하여 산업 전문가에게 문의하세요.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S ANALYSIS
4.2 PORTER'S MODEL
5 PIPELINE ANALYSIS FOR NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
6 EPIDEMIOLOGY
7 REGULATORY GUIDELINES FOR NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
7.1 U.S.
7.2 CANADA
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES
8.1.2 INCREASE IN THE PREVALENCE OF CANCERS
8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES
8.1.4 MULTIPLE THERAPIES
8.2 RESTRAINTS
8.2.1 HIGH COST OF TREATMENT
8.2.2 LACK OF AWARENESS ABOUT THE DISEASE
8.3 OPPORTUNITIES
8.3.1 DRUG APPROVALS
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.4 CHALLENGES
8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA
8.4.2 DIFFICULT REIMBURSEMENT
9 IMPACT OF COVID-19 ON THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
9.5 CONCLUSION
10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE
10.1 OVERVIEW
10.2 COMPRESSION THERAPY
10.2.1 BY PRODUCT
10.2.1.1 COMPRESSION PUMPS
10.2.1.2 COMPRESSION GARMENTS
10.2.1.2.1 COMPRESSION STOCKINGS
10.2.1.2.2 COMPRESSION SLEEVES
10.2.1.2.3 OTHERS
10.2.1.3 COMPRESSION BANDAGES & WRAPS
10.2.1.4 OTHERS
10.2.2 BY TECHNIQUE
10.2.2.1 STATIC COMPRESSION THERAPY
10.2.2.2 DYNAMIC COMPRESSION THERAPY
10.3 SURGERY
10.3.1 LYMPHOVENOUS TRANSPLANT
10.3.2 LYMPHATICOVENOUS ANASTOMOSIS
10.3.3 LIPOSUCTION
10.3.4 OTHERS
10.4 DRUG THERAPY
10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
10.4.2 RETINOIDS
10.4.3 ANTIBIOTICS
10.4.4 OTHERS
10.5 LASER THERAPY
10.6 OTHERS
11 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 SECONDARY LYMPHEDEMA
11.3 PRIMARY LYMPHEDEMA
11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE)
11.3.2 CONGENITAL LYMPHEDEMA
11.3.3 LYMPHEDEMA TARDA
12 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA
12.1 OVERVIEW
12.2 LOWER EXTREMITY
12.3 UPPER EXTREMITY
12.4 GENITALIA
13 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.3 GERIATRIC
13.4 PEDIATRIC
14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.3 INJECTABLE
14.4 TOPICAL
15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 SPECIALTY CLINICS
15.4 AMBULATORY SURGICAL CENTERS
15.5 OTHERS
16 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 PHARMACY STORES
16.3 DIRECT TENDER
16.4 OTHERS
17 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY REGION
17.1 OVERVIEW
17.2 U.S.
17.3 CANADA
17.4 MEXICO
18 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 SWOT ANALYIS
20 COMPANY PROFILE
20.1 TACTILE MEDICAL
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENT
20.1.5 CLINICAL TRIAL:
20.2 ESSITY (BSN MEDICAL GMBH)
20.2.1 COMPANY SNAPSHOT
20.2.2 PRODUCT PORTFOLIO
20.2.3 RECENT DEVELOPMENT
20.3 3M
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.3.5 NEW BUSINESS SEGMENT
20.3.6 ACQUISITION
20.4 CARDINAL HEALTH
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
20.5 LOHMANN & RAUSCHER GMBH & CO. KG
20.5.1 COMPANY SNAPSHOT
20.5.2 PRODUCT PORTFOLIO
20.5.3 RECENT DEVELOPMENT
20.6 AIROS MEDICAL, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.6.4 PRODUCT LAUNCH:
20.7 AVET PHARMACEUTICALS INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 BIOCOMPRESSION SYSTEMS
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.8.4 AGREEMENT
20.9 CONVATEC INC.
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT
20.1 HERANTIS PHARMA PLC
20.10.1 COMPANY SNAPSHOT
20.10.2 RECENT DEVELOPMENT
20.11 HUNTLEIGH HEALTHCARE LIMITED
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 JUZO
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 KOYA MEDICAL
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.13.4 APPROVAL
20.14 MEDI GMBH & CO. KG
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 MEGO AFEK LTD
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.15.4 APPLICATION LAUNCH:
20.16 PAUL HARTMANN AG
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENTS
20.17 SIGVARIS GROUP
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENTS
20.17.4 PRODUCT LAUNCHES:
20.18 SMITH +NEPHEW
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENT
20.19 THERMOTEK
20.19.1 COMPANY SNAPSHOT
20.19.2 PRODUCT PORTFOLIO
20.19.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
표 목록
TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT:
TABLE 2 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 16 U.S. LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 17 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 18 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 19 U.S. COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 20 U.S. SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 21 U.S. DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 22 U.S. LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 U.S. PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 U.S. LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 25 U.S. LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 26 U.S. LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 27 U.S. LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 U.S. LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 CANADA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 30 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 31 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 32 CANADA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 33 CANADA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 34 CANADA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 35 CANADA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 CANADA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 CANADA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 38 CANADA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 39 CANADA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 40 CANADA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 CANADA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 43 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 44 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 45 MEXICO COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 46 MEXICO SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 47 MEXICO DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 48 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 MEXICO PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 51 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 52 MEXICO LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 53 MEXICO LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 MEXICO LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : SEGMENTATION
FIGURE 2 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DROC ANALYSIS
FIGURE 4 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: REGIONAL VS COUNTRY ANALYSIS
FIGURE 5 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET : SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LYMPHEDEMA TREATMENT MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LYMPHEDEMA TREATMENT MARKET
FIGURE 14 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2021
FIGURE 15 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2020-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2021
FIGURE 19 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2021
FIGURE 23 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2020-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE
FIGURE 26 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2021
FIGURE 27 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2020-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 31 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 34 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2021
FIGURE 35 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 39 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 40 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL ,CAGR (2022-2029)
FIGURE 41 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 43 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 44 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE (2022-2029)
FIGURE 47 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.